132 related articles for article (PubMed ID: 20948271)
1. [Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients].
Tanimura K; Onda S; Mitsunobu M
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1991-3. PubMed ID: 20948271
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
Shima Y; Ohtsu A; Shirao K; Sasaki Y
Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
[TBL] [Abstract][Full Text] [Related]
4. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
Weber C; Zulian GB
Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
[TBL] [Abstract][Full Text] [Related]
5. Octreotide for malignant bowel obstruction: twenty years after.
Mercadante S; Porzio G
Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
[TBL] [Abstract][Full Text] [Related]
6. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
[TBL] [Abstract][Full Text] [Related]
7. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
8. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
9. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
[TBL] [Abstract][Full Text] [Related]
10. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
Massacesi C; Galeazzi G
Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
[TBL] [Abstract][Full Text] [Related]
11. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels.
Befon S; Mystakidou K; Lyra M; Tubanakis N; Vlahos L
Anticancer Res; 2000; 20(5C):4039-46. PubMed ID: 11268498
[TBL] [Abstract][Full Text] [Related]
12. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
Mercadante S
J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
[No Abstract] [Full Text] [Related]
13. Can octreotide be the first line treatment for chylothorax?
Leelahanon S; Petlek W; Sontimuang W; Pochanart P; Tepakorn V; Ruangpeg S
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S741-5. PubMed ID: 14700175
[TBL] [Abstract][Full Text] [Related]
14. How to use octreotide for malignant bowel obstruction.
Ripamonti C; Mercadante S
J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
[No Abstract] [Full Text] [Related]
15. The role of octreotide in malignant bowel obstruction.
Krammer LM
Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174
[No Abstract] [Full Text] [Related]
16. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
[TBL] [Abstract][Full Text] [Related]
17. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V
Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235
[No Abstract] [Full Text] [Related]
18. Aggressive pharmacological treatment for reversing malignant bowel obstruction.
Mercadante S; Ferrera P; Villari P; Marrazzo A
J Pain Symptom Manage; 2004 Oct; 28(4):412-6. PubMed ID: 15471659
[TBL] [Abstract][Full Text] [Related]
19. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases.
Perlemuter G; Cacoub P; Chaussade S; Wechsler B; Couturier D; Piette JC
Arthritis Rheum; 1999 Jul; 42(7):1545-9. PubMed ID: 10403284
[TBL] [Abstract][Full Text] [Related]
20. The challenge of treating malignant bowel obstruction.
J Support Oncol; 2006 Feb; 4(2):83-4. PubMed ID: 16499129
[No Abstract] [Full Text] [Related]
[Next] [New Search]
